Study: U.S. provides faster access to oncology drugs than Europe

Thursday, July 12, 2012 11:01 AM

Cancer patients in the U.S. get faster access to more oncology drugs to treat their disease than patients in Europe, according to a recent study by the Boston-based Tufts Center for the Study of Drug Development.

In addition, the study found new oncology drug approvals in the U.S. outpaced European approvals by 33% between 2000 and 2011.

"While greater access to more treatment options is definitely a positive for patients in the U.S., it is not clear if greater access leads to better health outcomes," said Joshua P. Cohen, the research assistant professor at Tufts CSDD who conducted the analysis.

Cohen said the growing use of comparative effectiveness research, which provides information on the relative strengths and weaknesses of different medical technologies, could help close the gap between what is known and what is done in pharmaceutical care.

"Although more oncology drugs are available in the U.S., and the costs for a higher share of them are reimbursed, the evidence-based approach adopted by European systems have improved the affordability of drugs in Europe that are considered to be cost-effective," Cohen said.

Other findings of the study were:

  • Between 2000 and 2011, 40 oncology drugs received market approval in the U.S. compared to 30 in Europe.
  • Oncology drug prices in Europe, on average, are 9% lower than in the U.S.
  • Patient cost sharing is much lower in Europe than the U.S., where the average co-insurance rate per covered drug is 33%.
Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs